International ophthalmology · 2022
One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kıran Yenice Eşay, Petriçli İkbal Seza, Kara Caner
Аннотация
PURPOSE: To investigate the effects of laser photocoagulation (LPC) and intravitreal bevacizumab (IVB) therapy used in the treatment of retinopathy of prematurity (ROP) on the first age refraction values in our center.
METHODS: The preterm infants who received LPC (Group I) and IVB therapy (Group II) for ROP were evaluated, and the refraction results were retrospectively compared.
RESULTS: The study included 86 eyes of 45 infants with a mean birth week of 26.5 ± 2.1 weeks and a mean birth weight of 904 ± 223 g. Treatments were administered up to a mean PMA of 36.0 ± 2.4 and 35.3 ± 2.6 weeks in Group I and Group II, respectively. In the follow-up examinations, 1-year spherical, cylindrical, and spherical equivalent (SE) values were 0.1 ± 2.2 D, - 1.2 ± 0.9 D, and - 0.5 ± 2.0 D in Group I and 1.3 ± 1.7 D, - 1.1 ± 0.8 D, and 0.8 ± 1.7 D in Group II, respectively (P = 0.018 for spherical; P = 0.772 for cylindrical, and P = 0.009 for SE). The mean spherical power and SE were significantly higher in Group II for zone II disease (p = 0.005 and p = 0.002). In addition, according to the ROP stage, infants with Stage 3 ROP were found to be significantly more myopic than infants in Stage 2 ROP in Group I (p = 0.03).
CONCLUSION: In conclusion, this study supports that even 0.625 mg IVB for ROP causes less myopia compared to LPC. Consistent with the literature, it was observed that the stage and zone of ROP had a significant effect on the development of myopia.
METHODS: The preterm infants who received LPC (Group I) and IVB therapy (Group II) for ROP were evaluated, and the refraction results were retrospectively compared.
RESULTS: The study included 86 eyes of 45 infants with a mean birth week of 26.5 ± 2.1 weeks and a mean birth weight of 904 ± 223 g. Treatments were administered up to a mean PMA of 36.0 ± 2.4 and 35.3 ± 2.6 weeks in Group I and Group II, respectively. In the follow-up examinations, 1-year spherical, cylindrical, and spherical equivalent (SE) values were 0.1 ± 2.2 D, - 1.2 ± 0.9 D, and - 0.5 ± 2.0 D in Group I and 1.3 ± 1.7 D, - 1.1 ± 0.8 D, and 0.8 ± 1.7 D in Group II, respectively (P = 0.018 for spherical; P = 0.772 for cylindrical, and P = 0.009 for SE). The mean spherical power and SE were significantly higher in Group II for zone II disease (p = 0.005 and p = 0.002). In addition, according to the ROP stage, infants with Stage 3 ROP were found to be significantly more myopic than infants in Stage 2 ROP in Group I (p = 0.03).
CONCLUSION: In conclusion, this study supports that even 0.625 mg IVB for ROP causes less myopia compared to LPC. Consistent with the literature, it was observed that the stage and zone of ROP had a significant effect on the development of myopia.